Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 15, Number 6—June 2009

Letter

Extensively Drug-Resistant Acinetobacter baumannii

Yohei DoiComments to Author , Shahid Husain, Brian A. Potoski, Kenneth R. McCurry, and David L. Paterson
Author affiliations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA (Y. Doi, B.A. Potoski, D.L. Paterson); University of Toronto, Toronto, Ontario, Canada (S. Husain); Toronto General Hospital, Toronto (S. Husain); Cleveland Clinic, Cleveland, Ohio, USA (K.R. McCurry); University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia (D.L. Paterson); Royal Brisbane and Women’s Hospital, Brisbane (D.L. Paterson)

Main Article

Table

MICs and antimicrobial drug susceptibility for an extensively drug-resistant strain of Acinetobacter baumannii*

Drugs MIC, μg/mL Interpretation
Carbapanems
Imipenem >32 Resistant
Meropenem
>32
Resistant
Penicillins
Ampicillin/sulbactam 32 Resistant
Piperacillin/tazobactam
>256
Resistant
Cephalosporins
Ceftazidime 48 Resistant
Cefepime
16
Intermediate
Aminoglycosides
Gentamicin >256 Resistant
Tobramycin >256 Resistant
Amikacin
>256
Resistant
Others
Ciprofloxacin >32 Resistant
Tigecycline 2 Intermediate
Colistin >1,024 Resistant

*Susceptibility testing was performed by using the Etest (AB Biodisk, Solna, Sweden), except for colistin, for which the standard agar dilution method was used. Interpretation was according to breakpoints provided by the Clinical and Laboratory Standards Institute (CLSI; Wayne, PA, USA). No tigecycline breakpoints for Acinetobacter spp. are provided by the CLSI, the European Committee on Antimicrobial Susceptibility Testing (Basel, Switzerland), or the US Food and Drug Administration (Silver Spring, MD, USA). Breakpoints of the British Society for Antimicrobial Chemotherapy (Birmingham, UK) are indicated for tigecycline.

Main Article

TOP